Navigation Links
Sangamo BioSciences to Present at the Piper Jaffray Health Care Conference
Date:11/20/2007

RICHMOND, Calif., Nov. 20 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at 11:00 am (ET) on Wednesday, November 28, 2007 at the Piper Jaffray 19th Annual Health Care Conference in New York.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on cancer and HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing seq
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
2. Sangamo BioSciences to Present at the UBS Global Life Sciences Conference
3. Sangamo BioSciences to Present at the 2007 BIO InvestorForum
4. Sangamo BioSciences Announces Third Quarter 2007 Conference Call and Webcast
5. Sangamo BioSciences Announces ZFP Therapeutic Data From Nerve Regeneration Program at Society for Neuroscience Meeting
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
8. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
11. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...ire/--Reportlinker.comannouncesthatanewmarketresea...ioethanolMarketAnalysisandForecaststo2013 ,, ...anol-Market-Analysis-and-Forecasts-to-2013.html ,...013 ,, Summary ,, Thereportprovidesdetaile...dtheBrazilbioethanolmarketinparticular.Italsohelps...
(Date:11/24/2009)...n German . , Whether it,s CD packaging, con...Frequency Identification) are increasingly finding...le to label objects or goods and identify them aut...nner can read and process the data contained in th...r production conditions of up to 100 degrees Celsi...
(Date:11/24/2009)...ssador to also Visit Detroit , ... Appia, French Ambassador for International Invest... Agency, , , , ,What: Ambassador Appia is availab...ss initiatives adopted by France to further develo... innovation and development., , ,When: Available f...
(Date:11/24/2009)...4/PRNewswire/--Twomoreprestigiousuniversitieshavej...ardandcareerssiteforlifescienceprofessionals. ,...thejobboard,joining28othermajorlifesciencetraining...er.com ,isonlyforpost-graduatesinthelifesciences.W...nternet,BioCareerCenteristheonlyonethatserveslifes...
Breaking Biology Technology:Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 3Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 4Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 5Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 6Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 7Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 8Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 9Intelligence inside metal components 2Two Major Universities Join Nation's Leading Postgrad Bio Job Board 2
...care Policy, SAN CARLOS, Calif., April 8, 2008 T...) have approved at-home sleep testing,for obstruct...d that,suspected sleep apnea sufferers undergo fac... continuous positive airway pressure (CPAP) treatm...attended home monitoring devices.,This decision wi...
...iotechnologies, Inc. (MBI) is pleased to announce ... at the Biodiversity Institute of Ontario,Universi...n MBI,s early,access program for the Apollo 100 ST...automated and integrated system for DNA sample pre...BI,s MOV(TM),(Microscale-On-Chip-Valve) technology...
...utics, Inc., a,privately held ophthalmic-focused b...entation of data from two Phase 3 clinical trials ... 0.05%, a topical steroid in,the treatment of post...ven,in a presentation by Michael Korenfeld, MD dur...e Surgery Annual Symposium in Chicago, Illinois., ...
Other Biology Technology:Medicare Approves in Home Sleep Apnea Testing 2Canadian Centre for DNA Barcoding to Participate in Microchip Biotechnologies Early Access Program for Microchip-Based DNA Sample Preparation and Cycle Sequencing 2Sirion Therapeutics Highlights Pivotal Trial Results of Durezol(TM) at the American Society of Cataract and Refractive Surgery Annual Symposium 2Sirion Therapeutics Highlights Pivotal Trial Results of Durezol(TM) at the American Society of Cataract and Refractive Surgery Annual Symposium 3
(Date:11/23/2009)...NNATINew research presents strong evidence that th...oth outdoor traffic-related pollution and indoor e... one or the other exposure alone. , Environmen...ati (UC) College of Medicine have shown that child... particles and indoor endotoxin during early life ...
(Date:11/23/2009)...E, Calif. -- More than 160 participants gathered t... Keck FUTURES INITIATIVE conference. This year,s t...ists, engineers, and medical researchers to explor...urrounding the emerging field of synthetic biology...ology at Princeton University and this year,s conf...
(Date:11/23/2009)...ON, WI, November 16, 2009 -- A USDOE and USDA stud..., idle cropland, and cropland pasture could be con...nnial grasses, such as switchgrass, from which bio...tock. Economically viable production of a perennia...ies of biomass are removed annually is expected to...
Breaking Biology News(10 mins):Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2Synthetic biology offers new opportunities for interdisciplinary collaboration 2Switchgrass produces biomass efficiently 2Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Onco 14899 1Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Onco 14899 2Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Onco 14899 3Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Onco 14899 4Shamir Optical Industry Ltd Reports Third Quarter 2009 Results 6374 1Shamir Optical Industry Ltd Reports Third Quarter 2009 Results 6374 2Shamir Optical Industry Ltd Reports Third Quarter 2009 Results 6374 3Shamir Optical Industry Ltd Reports Third Quarter 2009 Results 6374 4Shamir Optical Industry Ltd Reports Third Quarter 2009 Results 6374 5Shamir Optical Industry Ltd Reports Third Quarter 2009 Results 6374 6Shamir Optical Industry Ltd Reports Third Quarter 2009 Results 6374 7Shamir Optical Industry Ltd Reports Third Quarter 2009 Results 6374 8Shamir Optical Industry Ltd Reports Third Quarter 2009 Results 6374 9Shamir Optical Industry Ltd Reports Third Quarter 2009 Results 6374 10instaCare Corp Continues Turnaround Reports 58 25 Revenues Increase for First Three Quarters 6370 1instaCare Corp Continues Turnaround Reports 58 25 Revenues Increase for First Three Quarters 6370 2
... Dr. Francois Bolduc keeps more than 300,000 fruit...tes their genes and then tests their mental abilit...ike a comic book villain, but Bolduc is no mad sci...erta,s Faculty of Medicine & Dentistry, Bolduc has... called FMR1 in a fruit fly,s brain will wipe out ...
... Increasing pressures from climate change will rea...g a significant decline in the health of the plane...s in an international report issued today. , Rel...and the International Coral Reef Initiative, inter... "Status of Coral Reefs of the World: 2008" provid...
... This release is available in French . , Mont...an stunt growth and foster weight gain during pube...urnal of Clinical Endocrinology & Metabolism . Eve...m the McGill University Health Centre (MUHC) and t...ir study, vitamin D deficiency was found to cause ...
Other Biology News:'Fly guy' makes memory breakthrough 2Time running out on coral reefs as climate change becomes increasing threat 2Time running out on coral reefs as climate change becomes increasing threat 3Lack of vitamin D causes weight gain and stunts growth in girls 2
Bsu36 I from Promega
Multiskan EX from Thermo Scientific
Mouse Anti-Ubiquitin, Multi Monoclonal Antibody, Unconjugated, Clone FK2 from Assay Designs/Stressgen Bioreagents
T4 DNA Polymerase from Invitrogen
Biology Products: